This Article  • Full text  • PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (6)  • Contact me when this article is cited  Related Content  • Related articles  • Similar articles in this journal  Topic Collections  • Neurology  • Multiple Sclerosis/ Demyelinating Disease  • Rehabilitation Medicine  • Immunologic Disorders  • Alert me on articles by topic  Social Bookmarking   What's this?

Robert M. Herndon, MD; Lawrence Jacobs, MD
From the Department of Neurology, G.V. (Sonny) Montgomery, Veterans Affairs Medical Center, and the Department of Neurology, University of Mississippi Medical School, Jackson, (Dr Herndon); and the Departments of Neurology, Buffalo General Hospital and the State University of New York, Buffalo (Dr Jacobs).

Arch Neurol. 1998;55:1581-1583.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

TWO IFNs have recently been approved in the United States and Europe for treatment of MS. Whether to use these drugs, which drugs to use, and how to use them remains controversial. Interferon -1b (Betaseron, Berlex, Richmond, Calif) and IFN--1a (Avonex, Biogen, Cambridge, Mass) were approved based on independent trials using different methods and end points, but both support the effectiveness of IFNs as a class of drugs in the treatment of MS. The IFN--1b trial¹ was designed to show the effect of IFN--1b on acute attacks in patients with MS, and the IFN--1a trial² was designed to show the effect of IFN--1a on the physical disabilities of those patients. The course of MS extends through decades, leading to significant disability with progressive decline at varying rates. Clinical trials run for 2 to 3 years. Trial end points . . . [Full Text of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

RELATED ARTICLES

Interferons in the Treatment of Multiple Sclerosis: Do They Prevent the Progression of the Disease?
George Rice and George Ebers
Arch Neurol. 1998;55(12):1578-1580.
EXTRACT | FULL TEXT  

Interferons in the Treatment of Multiple Sclerosis
Vladimir Hachinski
Arch Neurol. 1998;55(12):1583.
EXTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Management of multiple sclerosis across managed care and fee-for-service systems
Vickrey et al.
Neurology 2000;55:1341-1349.
ABSTRACT | FULL TEXT